Cerus Corp. is a biomedical products company, which is engaged in developing and commercializing the INTERCEPT blood system. The INTERCEPT blood system is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. It markets and sells the INTERCEPT blood system for both platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA. [Source: MarketWatch]
Company Website: http://www.cerus.com